Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTRIPHYLLINE PEDIATRIC vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Symptomatic relief and prevention of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
AEROLONE is not a recognized drug; no standard dosing available.
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP1A2, CYP2E1, and CYP3A4; major metabolite is 1-methyl-3-propylxanthine; exhibits non-linear kinetics at high doses.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
55-65% (primarily albumin).
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.4-0.6 L/kg (increased in premature neonates and hepatic disease).
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 90-100%; Sustained-release: 80-95% (relative to immediate-release).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No specific guidelines; consider dose reduction in severe renal impairment (GFR <30 m L/min) to avoid accumulation.
No data; not applicable.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75% or avoid use.
No data; not applicable.
1-9 years: 4 mg/kg/dose orally every 6 hours; 9-16 years: 3 mg/kg/dose orally every 6 hours; adjust based on serum theophylline levels (target 5-15 mcg/m L).
No data; not applicable.
Start at 200 mg orally every 12 hours (extended-release) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
No data; not applicable.
No FDA boxed warning.
None
Risk of toxicity (seizures, cardiac arrhythmias) at serum levels >20 mcg/m L,Reduce dose in hepatic impairment, heart failure, and with drugs that inhibit metabolism (e.g., cimetidine, ciprofloxacin),Monitor serum theophylline concentrations
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to oxitriphylline or any xanthine,Active peptic ulcer disease,Seizure disorder (unless adequately controlled)
Hypersensitivity to arformoterol or any component of the formulation
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate). High-fat meals may delay absorption; consistency in timing relative to meals is recommended. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance, reducing efficacy.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Oxtriphylline, a theophylline derivative, is classified as pregnancy category C. First trimester: Limited data, no known major malformations in humans; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No specific risks, but maternal respiratory depression and fetal tachycardia may occur with high doses. Perinatal: Apnea, irritability, and jitteriness reported in neonates due to transplacental passage.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline (active metabolite) is excreted into breast milk; M/P ratio approximately 0.6-0.8. Peak milk concentration occurs 2-3 hours after dose. Recommendations: Caution in preterm infants due to immature clearance; observe for irritability, insomnia, or feeding intolerance. Avoid if maternal dose exceeds moderate levels.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Pregnancy may reduce clearance and increase half-life of theophylline; volume of distribution increases slightly. Consider 20-30% dose reduction and monitor levels to avoid toxicity (target trough 8-12 mcg/m L). Third trimester: Dose may need further adjustment; postpartum levels may decrease (clearance returns to prepregnancy levels).
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Oxtriphylline is the choline salt of theophylline, providing 64% anhydrous theophylline by weight. Monitor serum theophylline levels, maintaining therapeutic range 5-15 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders unless on anticonvulsants. Taper dose to avoid rebound bronchospasm. Use with caution in hepatic impairment, COPD, and elderly, as clearance is reduced.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid taking with large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report symptoms of toxicity: persistent nausea, vomiting, severe headache, rapid or irregular heartbeat, or seizures.,Do not change brands or formulations without consulting your healthcare provider.,Inform all healthcare providers that you are taking this medication.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
"Oxtriphylline, a xanthine derivative, is a prodrug of theophylline and is primarily metabolized by hepatic cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, induces CYP3A4 and other metabolic enzymes, potentially increasing the clearance of oxtriphylline's active metabolite theophylline. This reduction in theophylline exposure may decrease its bronchodilator efficacy, leading to worsening of respiratory symptoms in patients with asthma or COPD."
"Oxtriphylline, a xanthine bronchodilator, is metabolized primarily by CYP1A2 and CYP3A4. Azithromycin, a macrolide antibiotic, can inhibit CYP3A4, leading to decreased clearance of oxtriphylline and increased plasma concentrations. This may result in dose-related toxicity, including nausea, vomiting, tachycardia, and seizures."
"Oxtriphylline, a xanthine derivative used as a bronchodilator, may inhibit the metabolism of abiraterone, a CYP3A4 substrate, leading to increased serum concentrations of abiraterone. This elevation can potentiate the risk of abiraterone-related adverse effects such as hepatotoxicity, hypertension, hypokalemia, and fluid retention. Additionally, Oxtriphylline's own clearance may be affected, increasing the likelihood of xanthine toxicity manifesting as nausea, vomiting, or cardiac arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTRIPHYLLINE PEDIATRIC vs AEROLONE, answered by our medical review team.
OXTRIPHYLLINE PEDIATRIC is a Bronchodilator that works by Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTRIPHYLLINE PEDIATRIC and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTRIPHYLLINE PEDIATRIC is: 200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTRIPHYLLINE PEDIATRIC and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTRIPHYLLINE PEDIATRIC is classified as Category C. Oxtriphylline, a theophylline derivative, is classified as pregnancy category C. First trimester: Limited data, no known major malformations in humans; animal studies show no terat. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.